In the areas of neurology, severe food allergies, seasonal allergies and îmmunology Mabylon seeks to enter collaborative efforts with academic and commercial entities, with the goal to advance human medicine and provide important solutions to unmet medical needs.

Mabylon started collaborating with Pfizer through its Pfizer Ignite offering,

a new end-to-end service for selected biotech companies. This allows us to leverage Pfizer’s extensive therapeutic development expertise to speed the progression of MY006.

SciNeuro and Mabylon announce a Collaboration and License Agreement → ​

Prof. Adriano Aguzzi, MD

Institute of Neuropathology

University Hospital of Zurich

Prof. Barbara Ballmer-Weber
Allergy Unit, Dermatological Clinic
University Hospital of Zurich

Ms. Angelica Dünner-Graf
Verein Erdnussallergie und Anaphylaxie

Dr. med. Thomas Hauser
Immunologie Zentrum Zürich

Prof. Pål Johansen, PhD
Dermatological Clinic
University Hospital of Zurich

Dr. med. Alice Köhli
Department of Allergy
University Children’s Hospital Zurich

Prof. Clotilde Lagier-Tourenne MD, PhD

Massachusetts General Hospital and Harvard Medical School

Prof. Magdalini Polymenidou, PhD

Department of Quantitative Biomedicine
University of Zurich

Fondation Acteria Award to Natascha Wuillemin, Executive VP Immunology at Mabylon AG,

For the best oral presentation in clinical immunology entitled 'Allergen-targeting antibodies for the treatment of peanut and pollen allergies' at the SSAI Annual Congress 2023 in Bern.

1st prize to Pascal Gasser, Scientist Immunology at Mabylon AG,

for Flash talk presentation entitled “MY006: a passive immunotherapy for the treatment of peanut allergy” at the EAACI Hamburg 2023.

PEANUT BETTER - First-of-a-kind prophylactic treatment for peanut allergy based on natural human antibodies

This project has received funding from the Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and innovation programme (Nr. E!114710).

Development of immunotherapy to fight ALS and FTLD

This project has received funding from the National Institutes of Health (NIH Appl. ID: 10041805).

Discovering novel antibodies derived from the human body itself to treat neurodegenerative diseases

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 888016.

1^st prize to Natascha Wuillemin, Executive VP Immunology at Mabylon AG,

for oral presentation entitled “Human monoclonal antibodies as prophylactic treatment for severe allergies” at the WIRM 2018 in Davos.

Development of therapeutic human antibodies against peanut allergy

This project has received funding from Innosuisse (Innovationsprojekt Nr. 25866.2 PFLS-LS).